not vested
Baxter International Inc (NYSE:BAX) goes all the way back to the Great Depression.
In 1931, two doctors got together and became the first company to develop and sell intravenous solutions commercially. Before that, only hospitals and university health centers made their own solutions and so they were never available for broader use.
Since those days, BAX has stuck close to its knitting. It’s still a leader in the IV space as well as other fundamental healthcare applications.
One of its most significant additions has been its renal portfolio for people with kidney disease or kidney failure.
What’s more, BAX has been in Asian markets for four decades now. That is a big competitive advantage, especially in China, where many companies have been ‘Johnny-come-latelys’ to China and the Chinese value long-term relationships and cooperation. Asia is where the healthcare boom will hit next.
The stock is up nearly 25% YTD and it is far from its potential.
Source: Investor Place